Crown Bioscience Invests in Commercial Leadership
Crown Bioscience, a JSR Life Sciences company, today announces the appointment of Alex Slater as Vice President of Business Development, North America and Europe. In this role, Mr Slater will be responsible for the continued growth within the Company’s existing services portfolio and for setting the foundation for the expansion of new services.
The investment in additional leadership within CrownBio’s commercial and strategic development division reflects the increasing breadth and scientific depth of the company's offerings, and an appreciation of the need for tailored solutions at both an account and territory level. The new position will complement recent expansions in CrownBio’s Marketing, Product Management and Scientific Engagement departments, and is part of the company’s broader commitment to ensure that their customers' experience is industry-leading.
Commenting on the appointment, Mike Prosser, Senior Vice President, Commercial and Strategic Development, said, “I am delighted to welcome Alex to the team, and to fill another crucial role for the company, during an exciting phase of CrownBio’s growth. Alex’s extensive leadership experience in the CRO industry, encompassing multiple phases of drug discovery and development, will be invaluable to us as we evolve our teams in line with market opportunity.”
Mr. Slater joins CrownBio from Biocellvia, where he was VP of the business development function. In previous roles, he has served as Global VP for Business Development at Eurofins and held multiple sales leadership positions at Covance/LabCorp.
“During my interview process I was impressed by the strength of the leadership team at CrownBio, their commitment to innovation and the value they place in their customers’ experience,” commented Alex. “Further, the business development team already in place at CrownBio is highly motivated and professional and in my capacity as VP of Business Development I look forward to working with them to accelerate the organization’s future expansion.”
About Crown Bioscience
Crown Bioscience, a JSR Life Sciences company, is a global drug discovery and development service company providing translational platforms to advance oncology, immuno-oncology and inflammatory disorders. With an extensive portfolio of relevant models and predictive tools, Crown Bioscience enables clients to deliver superior clinical candidates.
Find out more at: http://www.CrownBio.com
About Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
CA-QUANERGY-SYSTEMS3.8.2021 12:02:12 CEST | Press release
Quanergy Demonstrates the Industry First OPA-based Solid State LiDAR with 100 Meter Range
MOODY’S-ESG3.8.2021 10:16:06 CEST | Press release
Moody’s ESG Solutions Launches Solution to Help Investors Assess Alignment With UN Global Compact
BOEHRINGER-INGELHEIM3.8.2021 10:02:05 CEST | Press release
First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development
SES-NETWORKS/ORANGE3.8.2021 08:52:03 CEST | Press release
SES Networks Expands Partnership With Orange to Enhance Maritime Services
GOPHER-INVESTMENTS3.8.2021 08:02:12 CEST | Press release
Gopher Response to Statement by Playtech, Related Clarifications and Reasons Why Shareholders Should VOTE AGAINST the Consortium Offer
RELIEF3.8.2021 07:05:13 CEST | Press release
Relief Announces Receipt of U.S. FDA Orphan Drug Designation for the use of RLF-100 (aviptadil) in the Treatment of Sarcoidosis
P.I.-WORKS3.8.2021 07:02:06 CEST | Press release
Smart Engages P.I. Works for Expanded Network Automation Solution
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.Visit our pressroom